🚚 Free Worldwide Shipping on All Orders!Shop Now
1 / 44
+39
Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinics (Volume 38-4)**
Pages: 240,
Specialty: Rheumatology,
Publisher: Elsevier,
Publication Year: 2006,
Cover: Hardback,
Dimensions: 160.02x231.14x15.24mm
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today - drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.show more
Specialty: Rheumatology,
Publisher: Elsevier,
Publication Year: 2006,
Cover: Hardback,
Dimensions: 160.02x231.14x15.24mm
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today - drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.show more
Pages: 240,
Specialty: Rheumatology,
Publisher: Elsevier,
Publication Year: 2006,
Cover: Hardback,
Dimensions: 160.02x231.14x15.24mm
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today - drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.show more
Specialty: Rheumatology,
Publisher: Elsevier,
Publication Year: 2006,
Cover: Hardback,
Dimensions: 160.02x231.14x15.24mm
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today - drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.show more
$14.70
Original: $42.00
-65%Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinics (Volume 38-4)**—
$42.00
$14.70Description
Pages: 240,
Specialty: Rheumatology,
Publisher: Elsevier,
Publication Year: 2006,
Cover: Hardback,
Dimensions: 160.02x231.14x15.24mm
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today - drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.show more
Specialty: Rheumatology,
Publisher: Elsevier,
Publication Year: 2006,
Cover: Hardback,
Dimensions: 160.02x231.14x15.24mm
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today - drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.show more
